AZ’s Farxiga Gets FDA Priority Review For Heart Failure
Moves Ahead of Rival SGLT2 Inhibitors
AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.
You may also be interested in...
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
The latest drug development news and highlights from our US FDA Performance Tracker.
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.